Damora Therapeutics, Inc. Common Stock (DMRA)

• Market cap: $1.14B
• 1 day: -1.41%
• 5 days: -29.31%
• 1 month: -36.9%
• 3 months: -34.54%
• 6 months: 531%
• Year to date: -13.24%
• 1 year: 357.25%
• 5 years: -89.56%
• 10 years: -94.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Employees: 5